Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DEPO ($6.4954 AH) - today was the 4th day of consolidation after the last leg up. From looking at the charts, we may have one more day of consolidation, then the next leg up begins.
DEPO ($6.32) - very nice grab there imo.
DEPO ($6.55) - I just talked to IR and we can expect to hear something soon regarding the resupply of Glumetza 500mg. DM-1992 Phase 1 results appear to be on track for release in Q1 and they are eagerly awaiting the FDA decision at the end of the month (18 trading days) for DM-1796. Regarding the Merck filing I referenced, that was already completed and DEPO received a $2.5M milestone payment.
DEPO ($5.51) - great start to January with many more near-term catalysts...
1) Merck will file a Januvia & Metformin combination.
2) Phase 1 results for DM-1992 (partially funded by the Michael J Fox Foundation) should be released in Q1 2011. This is their novel formulation of Levodopa/Carbidopa, which has been the drug of choice & well recognized as the best drug for Parkinson's Disease. The drug has several has significant limitations with inconvenient dosing (4-6 times daily) and mediocre efficacy.
3) Glumetza 500mg resupply.
4) Additional analyst coverage very possible.
5) and of course the biggie, January 30th PDUFA date of DM-1796.
ARIA ($5.20) - ARIAD Pharmaceuticals, Inc. at JP Morgan HealthCare Conference 01/12/11 at 10:30 a.m. PT
They could be presenting the Phase III data at this conference next week. With ARIA focused on cancer, positive Phase III data could really propel the stock. Investors go crazy for cancer stocks. Given the prior data results, I'm looking for positive data results this round also. Their financials look outstanding.
DEPO ($6.42) - based on the DD I have performed, I plan to hold my shares through the FDA decision.
CPIX - NASHVILLE, Tenn., Dec. 30, 2010 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has implemented a recall of 6 lots of Acetadote® (acetylcysteine) Injection, the Company's injectable treatment to prevent or lessen liver injury after ingestion of a potentially toxic quantity of acetaminophen. Cumberland informed the U.S. Food and Drug Administration (FDA) of its plans to voluntarily recall these lots of Acetadote as a precautionary measure based on observed particulate matter found in a very small number of vials.
Happy New Year everyone! Be safe!
DEPO ($6.41) - Only 19 trading days to PDUFA after today. January should be a great month for longs.
DEPO ($6.50) - loving the churn here, just as expected. I wouldn't be surpised to see some analysts initiating/reiterating coverage on DEPO in early January.
DEPO ($6.521) - time for the chart to consolidate here. Would like to see a few days of churn in this range, before the next leg up.
DEPO also has an SPA in place with the FDA for Serada, which is very positive.
DEPO ($6.56) - regarding the 3 catalysts below, numbers 1 and 3 could see news drop anyday now. Regarding number 2, I've been doing some reading up on this and it looks very promising. Long way to go, but looks good. I read that the Michael J. Fox Foundation helped to fund part of the Phase 1 trial.
The three catalysts that are expected to occur prior to the January 30th PDUFA date of DM-1796 are:
1) Merck will file a Januvia & Metformin combination in the 4Q 2010 or early 2011.
2) Phase 1 results for DM-1992 should be released in Q1 2011. This is their novel formulation of Levodopa/Carbidopa, which has been the drug of choice & well recognized as the best drug for Parkinson's Disease. The drug has several has significant limitations with inconvenient dosing (4-6 times daily) and mediocre efficacy.
3) Glumetza 500mg resupply to occur in 4Q 2010.
DEPO ($6.62) - fyi, both of their currently marketed drugs (Glumetza and Proquin XR) were approved by the FDA on the 1st try.....no denials, no CRL's!!
DEPO ($6.38) - I love the Serada (Phase 3) potential for 2011 and love the big named partners too.
DEPO ($6.38) - AVNR had a much larger short interest, relative to the float. Obviously, anything is possible, but I don't think we see a raid here. If so, it's good to have $ avail to add shares during the raid. During the AVNR raid, the pps was halted at nearly the same price the raid started at. It caught me off guard, but not anymore. We've learned from that raid. Regarding the run-up, it was more of a walk-up, consolidating daily, which is very healthy. DEPO has a lot going for it, not just this PDUFA in January. So, overall, I'd call it a very strong long-term hold during 2011. Good luck to you.
DEPO - next resistance is $6.34, then $6.43.
DEPO short interest increased by 20.55%
New: 2,961,900
Prior: 2,457,000
RGEN ($4.75 from $3.93 DD Alert) - continues to rip it up going into January.
That really puts it into perspective. Nice comparison. Thanks.
DEPO - then next resistance levels at $6.10, then $6.20. It's really starting to open up now. I'm expecting bigger % surges in the coming weeks. 34 days to PDUFA.
CHCI looking good here.
Happy Holidays everyone! Enjoy your weekend!!
XOMA - or not on the profit taking...lol!!!! Amazing to watch.
XOMA - yes, according to shortsqeeze, not many shorts. However, the intraday shorts are not included here. I agree with profit taking, RSI and STO getting really high here.
XOMA - amazing call here baggers. Well done.
XOMA - looks like an all-out short squeeze. Haven't seen something like this in a while.
DEPO ($5.79) - based on the data vs. the currently approved competition, if FDA approved (I expect approval), I expect them to dominate the market quickly. Why? 4 strong reasons....
1) equal or better pain relief scores (DM1796 reduced pain scores by 2.1 points, where as its competitor Neurontin achieved pain reduction scores of 2.2-2.3 points and Lyrica achieved a 1.8-2.2 reduction)
2) greatly reduced dizziness side effect scores (10.95 of patients recording dizziness, whereas Neurontin and Lyrica produced results of 31-33% and 12-28%)
3) somnolence advantage (4.5% experienced the problem in comparison to 17-20% and 15-24% of Neurontin and Lyrica patients)
4) DEPO drug is once daily vs. 2-3 times daily for the competitors.
If you were a doctor, which would you prescribe for your patient? No brainer here.
Stock Market Holiday Schedule 2011 (market is also closed tomorrow, Dec 24, 2010)
New Year's Day -
Martin Luther King, Jr. Day January 17, 2011
Presidents' Day February 21, 2011
Good Friday April 22, 2011
Memorial Day May 30, 2011
Independence Day July 4, 2011
Labor Day September 5, 2011
Thanksgiving Day November 24, 2011
Christmas December 26, 2011 (Observed)
New Years' Day (January 1, 2011) falls on a Saturday. The rules of the exchange state that when a holiday falls on a Saturday, the preceding Friday is observed, unless the Friday is the end of a monthly or annual accounting period. Friday, December 31, 2010 is the end of both a monthly and annual accounting period. The exchanges will be open that day as well as the following Monday.
RGEN ($4.39) - continues to uptrend.
APRI - sure did hit some major resistance here.
APRI - solid news out late yesterday. Already up 8.1% in pre-market and looking VERY bullish here.
XOMA ($4.74) - there is clearly more to this than meets the eye.
XOMA ($4.50) WOW is all I can say!!!
CORT is a good example between positive results for a Phase 3 drug vs. a Phase 2 drug.
RGEN ($4.10) +2% today. Seems to be heating up a little heading into January. (link back for DD post)
DEPO ($5.87) - looks like BATS out of the way now..looking good with 40 days left to PDUFA.
DEPO - looking forward to analysts jumping on the DEPO ban wagon. Should happen soon enough with less than 6 weeks to the PDUFU date.
DEPO ($5.76) - very healthy pullback and consolidation here. It's like clockwork on the chart. < 6 weeks to go now!!!
CLDA - Short Interest
Prior 2,457,800
New 2,578,400
+4.91% increase in shorts.
This is about $41M in shorts, which is pretty huge.
The action today was clearly shorting. I watched it closely and they did everything they could to bring it down. I actually got out near the end of the day. I didn't like the break of support of the 200 day and it's impossible to fight this kind of $ shorting it. I doubt they are done. I can see them possibly raiding this at some point. I'm moving CLDA to "possible bear raid" play. If it happens, I'll be ready to capitalize on the raid. I think there's a good chance of approval on this one too.